kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
2,702
JPY
-148
(-5.19%)
Mar 13, 3:30 pm JST
16.95
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
2,711
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
19.8
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
2,780 JPY 17.47 USD
Previous Close Mar 12
2,850 JPY 17.92 USD
High Mar 13, 12:53 pm
2,940 JPY 18.44 USD
Low Mar 13, 9:05 am
2,655 JPY 16.69 USD
Volume
2,399,900
Trading Value
6.68B JPY 0.04B USD
VWAP
2781.79 JPY 17.45 USD
Minimum Trading Value
270,200 JPY 1,695 USD
Market Cap
0.08T JPY 0.50B USD
Number of Trades
9,391
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
3,542
1-Year High Dec 30, 2025
44,420
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,100 6,076,100 5523.73
Feb 27, 2026 100 6,172,100 61721.00
Feb 20, 2026 0 6,312,700
Feb 13, 2026 400 5,984,200 14960.50
Feb 6, 2026 0 6,007,800
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.